Log In
BCIQ
Print this Print this
 

ID93/GLA-SE

  Manage Alerts
Collapse Summary General Information
Company Infectious Disease Research Institute
DescriptionVaccine comprising ID93, a recombinant fusion-protein of 4 Mycobacterium tuberculosis antigens, plus IDRI's glucopyranosyl lipid A stable emulsion (GLA-SE) adjuvant
Molecular Target
Mechanism of Action 
Therapeutic ModalityPreventive vaccine: DNA vaccine
Latest Stage of DevelopmentPhase II
Standard IndicationTuberculosis
Indication DetailsVaccinate against tuberculosis (TB)
Regulatory Designation
PartnerAeras Global TB Vaccine Foundation

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
Total Number of DealsTotal Deal ValueTotal Upfront CashTotal Milestone Payments

1

0

0

0


 Deals Details
DateCompanies InvolvedDeal HeadlineTotal Deal ValueTotal Upfront CashTotal Milestone

05/14/2012

Undisclosed

Undisclosed

Undisclosed

Get a free BioCentury trial today